Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.

@article{Jabbour2014DapagliflozinIE,
  title={Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.},
  author={Serge A Jabbour and Elise Hardy and Jennifer Sugg and Shamik J. Parikh},
  journal={Diabetes care},
  year={2014},
  volume={37 3},
  pages={740-50}
}
OBJECTIVE To assess the efficacy and safety of dapagliflozin as add-on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase-4 inhibitor with or without metformin. RESEARCH DESIGN AND METHODS In this 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study with a 24-week blinded extension period, 432 patients were randomized to receive dapagliflozin 10 mg/day or placebo added to sitagliptin (100 mg/day… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS
87 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 87 extracted citations

Similar Papers

Loading similar papers…